High cure rate with 24 weeks of daclatasvir-based quadruple therapy in treatment-experienced, null-responder patients with HIV/hepatitis C virus genotype 1/4 coinfection: The ANRS HC30 quadrih study

Clinical Infectious Diseases

Volumn 61, Issue 5, 2015, Pages 817-825

  Piroth, Lionel ^a   Paniez, Hubert ^b   Taburet, Anne Marie ^c   Vincent, Corine ^b   Rosenthal, Eric ^d   Lacombe, Karine ^e   Billaud, Eric ^f   Rey, David ^g   Zucman, David ^h   Bailly, François ⁱ   Bronowicki, Jean Pierre ^j   Simony, Mélanie ^k   Diallo, Alpha ^k   Izopet, Jacques ^l   Aboulker, Jean Pierre ^b   Meyer, Laurence ^b   Molina, Jean Michel ^m  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c BICÊTRE HOSPITAL   (France)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^e HÔPITAL SAINT ANTOINE   (France)

^f NANTES UNIVERSITY HOSPITAL   (France)

^g UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^h FOCH HOSPITAL   (France)

ⁱ CROIX ROUSSE HOSPITAL   (France)

^j UNIVERSITY HOSPITAL OF NANCY   (France)

^k International Research and Collaboration unit   (France)

^l UNIVERSITÉ PAUL SABATIER   (France)

^m SAINT LOUIS HOSPITAL   (France)

more..

Author keywords

Asunaprevir; Cirrhosis; Daclatasvir; HCV; HIV

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ALBUMIN; ASUNAPREVIR; DACLATASVIR; EMTRICITABINE; ENFUVIRTIDE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; LAMIVUDINE; PEGINTERFERON ALPHA2A; RALTEGRAVIR; RIBAVIRIN; TENOFOVIR; VIRUS RNA; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE;

ADULT; ALBUMIN BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; ASTHENIA; BACTERIAL PNEUMONIA; BLOOD TRANSFUSION; BRAIN HEMATOMA; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; DECREASED APPETITE; DIARRHEA; DRUG RESPONSE; DRUG SAFETY; DRY SKIN; FATIGUE; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; KIDNEY FAILURE; LIMIT OF DETECTION; LIVER BIOPSY; LUNG ABSCESS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED INFECTION; NEUTROPENIA; NONHUMAN; PHARMACOLOGY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PYELONEPHRITIS; SIDE EFFECT; SPONDYLITIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THRUSH; VIRUS LOAD; CLINICAL TRIAL; COINFECTION; COMPLICATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; MULTICENTER STUDY; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; COINFECTION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84942014184     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ381     Document Type: Article

References (35)

1. Weber R, Ruppik M, Rickenbach M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med 2013; 14:195-207.
2. Morlat P, Roussillon C, Henard S, et al. Causes of death among HIVinfected patients in France in 2010 (national survey): trends since 2000. AIDS 2014; 28:1181-91.
3. Berenguer J, Zamora FX, Carrero A, et al. Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis. J Acquir Immune Defic Syndr 2014; 66:280-7.
4. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-28.
5. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
6. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465:96-100.
7. Hézode C, Hirschfield GM, GhesquiereW, et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut 2015; 64:948-56.
8. Pasquinelli C, McPhee F, Eley T, et al. Single and multiple ascending dose studies of the NS3 protease inhibitor, asunaprevir, in subjects with or without chronic hepatitis C. Antimicrob Agents Chemother 2012; 56:3670-81.
9. Bronowicki JP, Ratziu V, Gadano A, et al. Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C. J Hepatol 2014; 61:1220-7.
10. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366:216-24.
11. Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, BMS-790052, and the nonstructural protein 3 protease inhibitor, BMS-650032, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012; 55:742-8.
12. Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2013; 58:655-62.
13. Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014; 59:2083-91.
14. Manns M, Pol S, Jacobson IM, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014; 384:1597-605.
15. Lok AS, Gardiner DF, Hezode C, et al. Randomized trial of daclatasvir and asunaprevir with or without pegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol 2014; 60:490-9.
16. Trimoulet P, Belzunce C, Faure M, et al. Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients. HIV Med 2011; 12:506-9.
17. Trevino A, de Mendoza C, Parra P, et al. Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients. Antivir Ther 2011; 16:413-6.
18. Cotte L, Braun J, Lascoux-Combe C, et al. Telaprevir for HIV-HCV coinfected patients failing peginterferon-ribavirin (ANRS HC26 Telapre-VIH): an open-label, single-arm, phase 2 trial. Clin Infect Dis 2014; 59:1768-76.
19. Poizot-Martin I, Bellissant E, Colson P, et al. Boceprevir for previously treated HCV-HIV coinfected patients: the ANRS-HC27 BocepreVIH Trial [abstract 659LB]. In: 21st Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2014.
20. Dieterich D, Rockstroh JK, Orkin C, et al. Simeprevir (TMC435) with peginterferon/ribavirin in patients coinfected with HCV genotype-1 and HIV-1: a phase III study. Clin Infect Dis 2014; 59:1579-87.
21. Dieterich D, Nelson M, Soriano V, et al. STARTVerso4: faldaprevir and pegylated interferon alpha-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV. AIDS 2015; 29:571-81.
22. Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014; 312: 353-61.
23. Molina JM, Orkin C, Iser DM, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet 2015; 385:1098-106.
24. Naggie S, Cooper C, Saag M, et al. Ledipasvir/sofosbuvir for 12 weeks in patients coinfected with HCV and HIV-1 [abstract 152LB]. In: 2015 Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2015.
25. Wyles D, Ruane P, Sulkowski M, et al. Daclatasvir in combination with sofosbuvir for HIV/HCV coinfection: ALLY-2 Study [abstract 151LB]. In: 2015 Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2015.
26. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370:1973-82.
27. Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2014; 385:1075-86.
28. Dieterich D, Bacon B, Flamm S. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population [abstract 46]. In: American Association for the Study of Liver Diseases (AASLD) Liver Meeting, Boston, MA, 2014.
29. Flamm S, Bacon B, Dieterich D, et al. Evaluation of efficacy of sofosbuvir and simeprevir-based regimens in a real-life population of 345 HCV patients with cirrhosis; data from the TRIO network [abstract 983]. In: American Association for the Study of Liver Diseases (AASLD) Liver Meeting, Boston, MA, 2014.
30. Bourlière M, Sulkowski M, Omata M, et al. An integrated safety and efficacy analysis of >500 patients with compensated cirrhosis treated with ledipasvir/sofosbuvir with or without ribavirin [abstract 82]. In: American Association for the Study of Liver Diseases (AASLD) Liver Meeting, Boston, MA, 2014.
31. Kapoor R, Kohli A, Sidharthan S, et al. All oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID SYNERGY Trial [abstract 240]. In: American Association for the Study of Liver Diseases (AASLD) Liver Meeting, Boston, MA, 2014.
32. Hezode C, Fontaine H, Dorival C, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014; 147:132-42.
33. Karino Y, Toyota J, Ikeda K, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol 2013; 58:646-54.
34. McPhee F, Hernandez D, Yu F, et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology 2014; 58:902-11.
35. Kosaka K, Imamura M, Hayes CN, et al. Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1. J Viral Hepat 2015; 22:158-65.